An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection

Stopped Due to the bankruptcy of FITBiotech, the provider of the GTU DNA vaccine.

Conditions

• HIV-1-infection

Interventions

• BIOLOGICAL: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine
• BIOLOGICAL: GTU-MultiHIV B-clade vaccine + MVA HIV-B HIV vaccine+ Vedolizumab
• DRUG: Vedolizumab 300 MG [Entyvio]
• OTHER: Placebo

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]